Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy

Table 2 Multivariate Cox proportional hazards analysis for associations between covariates and survival endpoints

Covariate	Hazard ratio (95 % confidence interval)	P-value
Biochemical failure-free survival
Gleason sum 9 or 10	3.33 (1.62 – 6.85)	0.001
Clinical stage T3b/T4	2.17 (1.11 – 4.22)	0.02
Relapse-free survival
Gleason sum 9 or 10	4.43 (2.14 – 9.14)	<0.001
Prostate cancer-specific survival
Gleason sum 9 or 10	4.13 (0.87 – 19.58)	0.07
Duration of ADT ≥28 months	0.20 (0.05 – 0.81)	0.02
Overall survival
Age ≥65 years	3.57 (1.00 – 12.82)	0.05
Gleason 4 + 3	17.26 (1.11 – 268.69)	0.04
Gleason 4 + 4	14.67 (1.07 – 200.81)	0.04
Gleason sum 9 or 10	70.11 (3.49 – 1407.99)	0.005
Duration of ADT ≥28 months	0.15 (0.05 – 0.44)	0.001

Multivariable models adjusted for age at diagnosis, pre-treatment PSA, biopsy Gleason score, clinical stage, lymph node involvement, and duration of administration of ADT
Abbreviations: androgen deprivation therapy (ADT)
Threshold of p < 0.25 was used to exclude covariates from the final multivariable model, using backwards elimination

ISSN: 1748-717X